Zeltia

 Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product.[history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns.[history 3]

Zeltia, S.A.
TypeSociedad Anónima
Traded as
BMAD: ZEL
ISINES0184940817
IndustryPharmaceutical
FoundedVigo, Galicia, Spain (August 3, 1939)
Defunct2015
Headquarters
Madrid
, 
Spain
Area served
Worldwide
Key people
José Fernández Sousa-Faro (Chairman)
ProductsPharmaceuticals
RevenueIncrease US$176 million (2009)
Operating income
Increase (US$46.3) million (2009)
Net income
Increase (US$40.3) million (2009)
Total assetsIncrease US$302.9 million (2009)
Total equityDecrease US$59 million (2009)
SubsidiariesPharmaMar, Genómica, Sylentis, Zelnova, Xylazel
Websitewww.zeltia.com
Footnotes / references
[finan 1][history 1]

HistoryEdit

In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal.[1]

The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.


This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.